PhysVENeT: a physiologically-informed deep learning-based framework for the synthesis of 3D hyperpolarized gas MRI ventilation.

Journal: Scientific reports
PMID:

Abstract

Functional lung imaging modalities such as hyperpolarized gas MRI ventilation enable visualization and quantification of regional lung ventilation; however, these techniques require specialized equipment and exogenous contrast, limiting clinical adoption. Physiologically-informed techniques to map proton (H)-MRI ventilation have been proposed. These approaches have demonstrated moderate correlation with hyperpolarized gas MRI. Recently, deep learning (DL) has been used for image synthesis applications, including functional lung image synthesis. Here, we propose a 3D multi-channel convolutional neural network that employs physiologically-informed ventilation mapping and multi-inflation structural H-MRI to synthesize 3D ventilation surrogates (PhysVENeT). The dataset comprised paired inspiratory and expiratory H-MRI scans and corresponding hyperpolarized gas MRI scans from 170 participants with various pulmonary pathologies. We performed fivefold cross-validation on 150 of these participants and used 20 participants with a previously unseen pathology (post COVID-19) for external validation. Synthetic ventilation surrogates were evaluated using voxel-wise correlation and structural similarity metrics; the proposed PhysVENeT framework significantly outperformed conventional H-MRI ventilation mapping and other DL approaches which did not utilize structural imaging and ventilation mapping. PhysVENeT can accurately reflect ventilation defects and exhibits minimal overfitting on external validation data compared to DL approaches that do not integrate physiologically-informed mapping.

Authors

  • Joshua R Astley
    POLARIS, Department of Infection, Immunity & Cardiovascular Disease, The University of Sheffield, Sheffield, United Kingdom.
  • Alberto M Biancardi
    POLARIS, Department of Infection, Immunity and Cardiovascular Disease, The University of Sheffield, Sheffield, UK.
  • Helen Marshall
    POLARIS, Department of Infection, Immunity and Cardiovascular Disease, The University of Sheffield, Sheffield, UK.
  • Laurie J Smith
    POLARIS, Department of Infection, Immunity and Cardiovascular Disease, The University of Sheffield, Sheffield, UK.
  • Paul J C Hughes
    POLARIS, Department of Infection, Immunity and Cardiovascular Disease, The University of Sheffield, Sheffield, UK.
  • Guilhem J Collier
    POLARIS, Department of Infection, Immunity and Cardiovascular Disease, The University of Sheffield, Sheffield, UK.
  • Laura C Saunders
    POLARIS, Department of Infection, Immunity & Cardiovascular Disease, The University of Sheffield, Sheffield, UK.
  • Graham Norquay
    POLARIS, Department of Infection, Immunity & Cardiovascular Disease, The University of Sheffield, Sheffield, UK.
  • Malina-Maria Tofan
    Department of Oncology and Metabolism, The University of Sheffield, Sheffield, UK.
  • Matthew Q Hatton
    Department of Oncology and Metabolism, The University of Sheffield, Sheffield, UK.
  • Rod Hughes
    Early Development Respiratory, AstraZeneca, Cambridge, UK.
  • Jim M Wild
    Department of Oncology and Metabolism, The University of Sheffield, Sheffield, United Kingdom.
  • Bilal A Tahir
    POLARIS, Department of Infection, Immunity & Cardiovascular Disease, The University of Sheffield, Sheffield, United Kingdom.